Drug intelligence / Profile preview

DT2-SCT

Development stage: Phase 2
Lead developer: GIOSTAR
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

DT2-SCT is an autologous cell therapy consisting of adipose-derived mesenchymal stem cells (AD-MSCs) developed by GIOSTAR. The therapy is designed to treat Type 2 Diabetes Mellitus (T2DM) by leveraging the immunomodulatory and regenerative properties of stem cells to reduce insulin resistance and improve glycemic control. The treatment process involves collecting adipose tissue from the patient via liposuction, isolating and processing the stem cells, and then re-administering them through a single intravenous infusion. The goal of the therapy is to decrease systemic inflammation and improve the metabolic profile of patients, potentially reducing the need for exogenous insulin or oral glucose-lowering medications.

Other names: autologous adipose-derived mesenchymal stem cellsAD-MSCs

Beyond the preview

Go deeper on DT2-SCT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DT2-SCT.

Explore the full profile